Autumn Wills
Physician Assistant · Cape Girardeau, MONPI 1437286671
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,917 of the $36,767 with a category attached, or 81.4%. Novo Nordisk accounts for 95.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $16,924 and has fallen 64.4% since, to $6,017 in 2025. Among physician assistant clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $264.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$35K
- Abbott$289
- Corcept Therapeutics$232
- Sanofi-aventis U.S. LLC$135
- Lilly USA, LLC$124
- Insulet Corporation$101
- plus $614 from 11 others
What the payments were for
- Speaking & faculty fees$29,91781%
- Travel & lodging$3,56010%
- Food & beverage$3,2389%
- Education$320%
- Other$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $35,272 |
| Abbott | 16 | $289 |
| Corcept Therapeutics | 8 | $232 |
| Sanofi-aventis U.S. LLC | 5 | $135 |
| Lilly USA, LLC | 4 | $124 |
| Insulet Corporation | 5 | $101 |
| Novartis | 4 | $96 |
| Boehringer Ingelheim | 5 | $85 |
| Amgen | 5 | $76 |
| AstraZeneca(2 entities) | 4 | $74 |
| Xeris Pharmaceuticals, Inc. | 3 | $67 |
| Medtronic | 2 | $65 |
| Recordati_rare_diseases_inc. | 3 | $52 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Bayer | 1 | $22 |
| AbbVie | 1 | $20 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,767 in reported general payments places this provider in the 95th percentile of 1,380 physician assistant providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $137,415 |
| MounjaroTirzepatide | 95 | $114,724 |
| JardianceEmpagliflozin | 140 | $111,874 |
| TrulicityDulaglutide | 65 | $71,358 |
| FarxigaDapagliflozin Propanediol | 84 | $70,466 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $42,052 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $37,832 |
| JanuviaSitagliptin Phosphate | 46 | $32,152 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $31,634 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $26,049 |
| VascepaIcosapent Ethyl | 51 | $22,949 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $21,476 |
| Xigduo XrDapaglifloz Propaned/Metformin | 20 | $18,929 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $16,188 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $15,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $124 | $186,082160 claims |
| Novo NordiskOzempic, Rybelsus | $35,272 | $149,103136 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $85 | $127,617158 claims |
| AstraZenecaFarxiga | $74 | $70,46684 claims |
| AbbVieSynthroid | $20 | $6,194100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,380 physician assistant providers in Missouri.
Other physician assistant in Cape Girardeau
- Amy WillinghamCape Girardeau$12K
- Jennifer DavissonKansas City$343K
- Andrew BergLees Summit$245K
- Sileen DowisKansas City$117K
- Daniel BeckSikeston$114K
- Amee RozancO Fallon$101K
- Kimberly BrownSaint Louis$28K
- Marc ReitznerSpringfield$24K
- Justin AllphinOzark$23K
- Jacqueline CastagnoWentzville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.